The reduction in the price target by HC Wainwright, despite maintaining a Buy rating, suggests a tempered optimism about PLRX's short-term price potential. This adjustment is likely to influence investor sentiment negatively in the short term, as the lowered target may be interpreted as a sign of reduced growth expectations or emerging risks not previously accounted for.